Highest-materiality recent filing
Arrowhead Q2 revenue $73.7M, net loss $0.93; REDEMPLO strong; $930M capital raise; Madrigal license
Q2 revenue $73.7M (down 86% YoY); net loss $132.7M ($0.93 diluted EPS) vs prior-year income $370.4M ($2.75 EPS).
Arrowhead Q1 revenue $264M; REDEMPLO launched; $930M financing closed
Revenue $264M (vs $2.5M YoY); net income $30.8M ($0.22 diluted EPS) vs loss $173M.
Arrowhead issues $700M zero-coupon convertible notes due 2032; enters capped call to reduce dilution
Arrowhead issued $700M 0.00% convertible senior notes due 2032; conversion price ~$87.07 per share.
Arrowhead prices upsized $625M zero-coupon convertible notes and $216.6M equity offering
Net proceeds of ~$681.3M from $700M (including over-allotment) of 0.00% convertible notes due 2032.
ARO-INHBE + tirzepatide (n=4) achieved -9.4% weight loss at week 16 vs -4.8% with tirzepatide alone; visceral fat -23.2% vs -7.4%.
Arrowhead FY2025 revenue $829M on milestones; FDA approves first drug REDEMPLO
Revenue $829.4M in FY2025, up from $3.6M, driven by Novartis and Sarepta milestone payments.
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO for Familial Chylomicronemia Syndrome
REDEMPLO (plozasiran) approved by FDA as adjunct to diet to reduce triglycerides in adults with FCS.
Ionis sues Arrowhead for patent infringement over plozasiran, threatening FCS launch
Ionis filed complaint in Central District of California alleging Arrowhead's plozasiran infringes U.S. Patent No. 9,593,333.
Arrowhead files declaratory judgment suit against Ionis over '333 patent for plozasiran
Arrowhead filed a declaratory judgment action in Delaware against Ionis claiming the '333 patent is invalid and not infringed by plozasiran.
Arrowhead licenses ARO-SNCA to Novartis for $200M upfront, up to $2B milestones
Arrowhead receives $200M upfront; eligible for up to $2B in development, regulatory, sales milestones.
Arrowhead Q3 revenue $27.8M, net loss $1.26/sh; plozasiran PDUFA Nov 18, 2025
Revenue $27.8M (vs $0 YoY); net loss attributable $175.2M, or $1.26 diluted EPS (vs $1.38).
Arrowhead Q2 revenue $542.7M on Sarepta deal; plozasiran PDUFA Nov 18, 2025
Q2 revenue of $542.7M (vs $0 prior year) driven by $825M Sarepta licensing deal ($500M cash + $325M equity).
Arrowhead CFO Ken Myszkowski to retire May 13; Daniel Apel named new CFO
Ken Myszkowski will retire as CFO effective May 13, 2025, after 16 years; no disagreement cited.
Arrowhead Q1 net loss $173M; $825M Sarepta deal & plozasiran NDA accepted
Net loss of $173M ($1.39 diluted EPS), revenue $2.5M, operating loss $161.4M.
Arrowhead appoints Sarepta CEO Douglas Ingram as director
Douglas Ingram appointed to Arrowhead board effective Feb 6, 2025, per Investor Rights Agreement with Sarepta.
Arrowhead reports FY2024 net loss $599.5M; inks Sarepta deal, files plozasiran NDA
Net loss of $599.5M (-$5.00 diluted EPS) vs $205.3M loss (-$1.92) in FY2023.
Net loss of $170.8M ($1.38 diluted EPS) vs $102.9M ($0.96) a year ago; revenue nil vs $15.8M.
Arrowhead Q2 net loss $125.3M ($1.02/share) vs prior year net income $48.7M; revenue $0
Net loss of $125.3 million ($1.02 diluted loss per share) compared to net income of $48.7 million ($0.45 diluted EPS) in Q2 2023.
Ken Myszkowski notified Arrowhead Pharmaceuticals, Inc. (the “Company”) of his decision to retire as Chief Financial Officer of the Company, effective as of May 13, 2025
the Company determined that it would appoint Daniel Apel to serve as Chief Financial Officer of the Company
On February 5, 2025, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Douglas Ingram as a director of the Company, effective February 6, 2025.
Appointment of Hongbo Lu as a Director
Max materiality 0.95 · Median 0.75 · Most common event earnings